Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

Inflammatory bowel diseases (IBDs) cause significant morbidity and mortality. Aberrant NF-κB signalling is strongly associated with these conditions, and several established drugs influence the NF-κB signalling network to exert their effect. This study aimed to identify drugs that alter NF-κB signal...

Full description

Bibliographic Details
Main Authors: Katie Lloyd, Stamatia Papoutsopoulou, Emily Smith, Philip Stegmaier, Francois Bergey, Lorna Morris, Madeleine Kittner, Hazel England, Dave Spiller, Mike H. R. White, Carrie A. Duckworth, Barry J. Campbell, Vladimir Poroikov, Vitor A. P. Martins dos Santos, Alexander Kel, Werner Muller, D. Mark Pritchard, Chris Probert, Michael D. Burkitt, The SysmedIBD Consortium
Format: Article
Language:English
Published: The Company of Biologists 2020-11-01
Series:Disease Models & Mechanisms
Subjects:
inflammatory bowel diseases
nf-κb
drug repositioning
interdisciplinary research
organoids
macrolide
ulcerative colitis
crohn's disease
Online Access:http://dmm.biologists.org/content/13/11/dmm044040

Internet

http://dmm.biologists.org/content/13/11/dmm044040

Similar Items